Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

High-Dose Insulin Therapy: Is It Time for U-500 Insulin?

(2013) Wendy Lane et al.   Endocrine Practice

Reduced Risk of Hypoglycemia with Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: Meta-Analysis of Five Randomized Trials

(2012) Helena W. Rodbard et al.   Canadian Journal of Diabetes

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Uncovering undetected hypoglycemic events

(2012) Jeffrey Unger   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Barriers to Insulin Injection Therapy

(2009) Richard R. Rubin et al.   DIABETES EDUCATOR

Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus

(2009) W Crasto et al.   POSTGRADUATE MEDICAL JOURNAL